PubMed

[Chemoradiotherapy in treatment of cancer of the anal canal].

Authors

Gérard JP.

Journal

Cancer Radiother. 1998 Dec;2(6):708-12. Article in French.

Affiliation

Abstract

In the treatment of anal canal carcinoma, since the work of Nigro, the 5-fluorouracil-mitomycin C regimen is considered standard when applied concomitantly with radiotherapy. Surgery is used mainly to salvage the failures after irradiation. Two randomized European trials (EORTC, UKCCCR) have shown that the 5-fluorouracil-mitomycin C combination improves local control but not overall survival. The RTOG-ECOG trial has shown that mitomycin C improves local control when compared to 5-fluorouracil alone. This chemotherapy is responsible for a toxic death in 2% of cases. The 5-fluorouracil-cisplatin regimen will possibly represent an alternative to the 5-fluorouracil-mitomycin C. Ongoing trials will help to answer this question.

PMID

9922777 [PubMed - indexed for MEDLINE]
Full text: Elsevier Science
 Citation 4 of 107 Back to results 
Standard PubMed